AN2 Therapeutics (ANTX) Share-based Compensation (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 28.68% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 16.41% decrease from a year earlier, with the FY2025 full-year figure at $6.2 million, down 25.09% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.5 million, up from $1.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for ANTX reached as high as $6.5 million in Q2 2025 and fell as low as $449000.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $2.2 million across 5 years, with a median of $1.9 million in 2023.
• Across the five-year window, Share-based Compensation jumped 5512.5% in 2022 and declined 28.68% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $1.5 million in 2022, then soared by 51.63% to $2.2 million in 2023, then slipped by 20.25% to $1.8 million in 2024, then decreased by 21.35% to $1.4 million in 2025, then climbed by 4.29% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.5 million in Q1 2026, $1.4 million in Q4 2025, and $5.2 million in Q3 2025.